Section Arrow
CUE.NASDAQ
- Cue Biopharma Inc.
Quotes are at least 15-min delayed:2026/07/10 03:55 EDT
Pre Market
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 36.51
+1.16 (+3.28%)
Day High 
37 
Prev. Close
35.35 
1-M High
36.99 
Volume 
143.82K 
Bid
--
Ask
--
Day Low
31.29 
Open
35.33 
1-M Low
23.16 
Market Cap 
148.48M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 29.68 
20-SMA 28.46 
50-SMA 26.44 
52-W High 41.42 
52-W Low 4.971 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.53/-0.42
Enterprise Value
150.77M
Balance Sheet
Book Value Per Share
5.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
27.47M
Operating Revenue Per Share
0.91
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited6.36+3.18+100.00%-- 
Pre Market -- -- --
EVGNEvogene Ltd.0.5+0.0859+20.74%-- 
Pre Market -- -- --
RXRXRecursion Pharmaceuticals3.76+0.04+1.08%-- 
Pre Market -- -- --
IONSIonis Pharmaceuticals64.27-20.19-23.90%-- 
Pre Market -- -- --
BBIOBridgeBio Pharma90.17+11.84+15.12%-- 
Pre Market -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate forautoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.